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ABSTRACT
Objectives The objectives of this study were to evaluate 
treatment in patients on current programmatic multidrug- 
resistant tuberculosis (MDR- TB) regimen and verify 
eligibility for the 9- month regimen and therapeutic drug 
monitoring (TDM).
Methods We performed a retrospective chart review of 
patients with MDR- TB receiving standardised regimen 
at the German Nepal TB Project Clinic, Nepal, between 
2014 and 2016. Eligibility for the 9- month regimen and 
indications for TDM were evaluated.
Results Out of 107 available patients’ medical records, 
98 were included. In this centre, the MDR- TB treatment 
success rates were 69.0% in 2015, 86.6% in 2016 
and 86.5% in 2017. The median time to sputum smear 
conversion was 60 days (60–90 IQR) and culture 
conversion was 60 days (60–90 IQR). Observed side 
effects did not impact treatment outcomes. No difference 
in treatment success rates was observed between patients 
with predisposing risk factors and those without. Only 49% 
(36/74) of patients were eligible for the 9- month regimen 
and 23 patients for TDM according to American Thoracic 
Society guideline criteria.
Conclusions Nepalese patients with MDR- TB on 
ambulatory care had good treatment outcome after 
programmatic treatment. Implementation of the new WHO 
oral MDR- TB treatment regimen may further improve 
treatment results. The 9- month regimen and TDM should 
be considered as part of programmatic care.
INTRODUCTION
Tuberculosis (TB) is the leading infectious 
disease caused by Mycobacterium tuberculosis 
that kills more people than HIV/AIDS every 
year. In 2018, an estimated 10 million people 
developed TB and 1.2 million died from it.1 
Multidrug- resistant TB (MDR- TB), a form 
where the infecting strain is resistant to two 
important first- line drugs (isoniazid and 
rifampicin), has created havoc in TB control 
and has greatly hampered the TB elimination 
process.
Later generation fluoroquinolones (levo-
floxacin and moxifloxacin) are key drugs in 
both standardised (20–24 months duration), 
short course 9- month and all- oral 20- month 
regimens in use for treating MDR- TB.1 2 Levo-
floxacin and moxifloxacin containing regi-
mens had similar treatment outcomes in four 
published clinical trials.2–6 Although the role 
of gatifloxacin was believed to be critical in 
the success of the short 9- month regimen 
studied in Bangladesh, Niger and Cameroon, 
7–9 the drug is not included in the new 
WHO consolidated guidelines for the treat-
ment of drug resistance TB.1 With the new 
all- oral 20- month regimen which includes 
drugs like bedaquiline and delamanid, the 
overall proportion of adverse events was 
reasonably low compared with standardised 
Key messages
What is the key question?
 ► The study evaluated treatment in patients on cur-
rent programmatic multidrug- resistant tuberculosis 
(MDR- TB) regimen and verified eligibility for the 
9- month regimen and therapeutic drug monitoring 
(TDM).
What is bottom line?
 ► The standardised MDR- TB regimen appears well 
tolerated in patients; none of the adverse events 
resulted in a change of regimen. Implementation 
of the new WHO oral MDR- TB treatment regimen 
may further improve treatment results. The 9- month 
regimen and TDM should be considered as part of 
programmatic care.
Why read on?
 ► The study provides complete treatment outcome 
data of patients with MDR- TB along with all signifi-
cant clinical variables and drug susceptibility testing 
results (phenotypic and genotypic) make it relevant 
and provide a data- rich description of patients with 
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20–24 month regimen with injectable agents.10 11 More 
evidence is needed to assess the tolerability of the new all- 
oral regimen, especially in settings with limited resources 
where short 9- month regimen has demonstrated to be 
safe and effective.12 Furthermore, linezolid, a narrow 
therapeutic index drug, will be frequently used in the all- 
oral regimen; therefore, balancing efficacy and toxicity 
is crucial.13 14 Therapeutic drug monitoring (TDM) 
can be used as a tool to ensure target attainment while 
preventing toxicity.1 10 13 15–17
In the light of available evidence, it’s important to 
explore the link between various risk factors like diabetes 
mellitus, HIV, advanced age, low body weight and adverse 
events and treatment outcomes in patients under a 
standardised regimen for MDR- TB treatment in a local 
setting.1 2 Therefore, the aim of this study was to evaluate 
treatment outcomes of patients with MDR- TB on current 
programmatic regimen. Furthermore, this study aims to 
explore the eligibility of patients with baseline resistance 
to more than one first- line drug for the shorter 9- month 
regimen and evaluate if TDM could be recommended.
METHODS
Study population and study design
A retrospective chart review was performed for all 
patients with MDR- TB receiving levofloxacin as part of 
their standard MDR- TB regimen enrolled for treatment 
at the Nepal Anti- Tuberculosis Association/German 
Nepal TB Project (NATA/GENETUP), Kathmandu, 
Nepal, between April 2014 and December 2016. Patients 
received 750–1000 mg levofloxacin one time a day. The 
other drugs included in the regimen were kanamycin at 
a median dose of 750–1000 mg, cycloserine and ethion-
amide both at one time a day dose of 500–750 mg and 
pyrazinamide at 1200–1600 mg one time a day dosing. 
Patients with missing records/incomplete information 
were excluded, and those who had pre- XDR TB (Exten-
sively drug resistant) (with either fluoroquinolone resist-
ance or resistance to second- line injectable agents) were 
also excluded. In the GENETUP clinic, all patients were 
tested for HIV and diabetes mellitus as a standard proce-
dure. All patients with HIV were on antiretroviral therapy 
(tenofovir, lamivudine and efavirenz/dolutegravir- based 
regimen). Similarly, patients with diabetes mellitus were 
on hypoglycaemic agents.
Model of care and pharmacovigilance
Primarily, patients were treated as outpatients from the 
start of treatment. Residential facilities (included meals 
and monthly allowance of US$1.5) were provided to 
impoverished patients, those at the risk of treatment non- 
adherence and treatment failure. Due to limited room 
capacity, patients were qualified eligible for residential 
facilities on a case- by- case basis giving priority to those in 
dire need. This allowed healthcare providers at NATA/
GENETUP to closely monitor and manage MDR- TB 
treatment in vulnerable subpopulations. For patients 
in ambulatory care, adherence was ensured by keeping 
contact information of two additional patient relatives 
along with their home address details. In some cases, 
community members were contacted if both patient and 
patient parties were unreachable. Since TB is considered 
a public health threat in Nepal, seldom, police authori-
ties were involved to provide counselling to non- adherent 
patients.
Medication safety was evaluated by recording adverse 
reactions in a standardised adverse effect monitoring 
form, every month until treatment completion. On daily 
visits to GENETUP clinic for DOTS (Directtly Observed 
Treatment, Short Course) facilities, patients were given 
the opportunity to report serious side effects. Then, based 
on complaints and serum biochemistry results, offending 
agents were either discontinued for a period of time or 
replaced with other available drugs in the regimen.
Patient and public involvement
This being a retrospective study, patients were not 
involved.
Culture, DST, clinical variables and outcome
Before initiation of treatment, two sputum samples 
were collected from patients for culture and second- 
line drug susceptibility testing (DST), and subsequently 
every month until 8 months followed by 10, 12, 16, 18, 
20, 22 and 24 months for treatment monitoring by smear 
microscopy and culture on Löwenstein- Jensen media. 
Phenotypic first- line and second- line DST was carried out 
at the WHO critical concentrations.18 The genotypic DST 
(GenoType MTBDRplus) molecular line probe assay was 
used for diagnosis of isoniazid (katG and inhA gene), and 
rifampicin (rpoB gene) resistance. For second- line drugs, 
molecular line probe assay (Hain Life Science, Geno-
Type MTBDRsl) was used to identify resistance pattern 
to fluroroquinolones (gyrA gene), and aminoglycosides 
(rrs gene) and ethambutol (embB gene). Furthermore, 
the study evaluated impact of initial ethambutol resist-
ance on MDR- TB treatment outcomes. Clinical variables 
included age, body weight at admission, body weight 
after 8 months of treatment, body weight below 35 kg, 
gender, HIV status, comorbidities, prior anti- TB therapy 
and presence of cavitary lesions. To evaluate the safety of 
the multidrug regimen, all recorded adverse events and 
lab test results at three different time periods (baseline, 
third month and 5–8 months of treatment) were retrieved 
from the medical records.
The MDR- TB treatment outcomes are defined based on 
WHO guidelines adopted by the NTP (National Tuber-
culosis Programme), Nepal.19 This study used Laserson’s 
recommendations to note the treatment outcomes where 
deaths included all deaths irrespective of the cause during 
the course of MDR- TB treatment.20 Successful treatment 
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whereas unsuccessful outcome is characterised by failure, 
death, relapse, loss to follow- up or transfer out.
DST results on first- line and second- line drugs were 
obtained to evaluate potential eligibility of patients in 
a shorter 9- month MDR- TB regimen. Furthermore, an 
official clinical practice guideline from the American 
Thoracic Society was used to evaluate patients eligible 
for TDM. Criteria for TDM were patients with gastroin-
testinal problems that increase risk of malabsorption, 
concurrent HIV infection, impaired renal clearance, 
diabetes or patients not responding to MDR- TB therapy 
by the third month.16 21
Statistical analysis
The association of variables with treatment outcomes 
(successful/unsuccessful) was studied using univariate 
logistic regression analysis (SPSS, V.23.0 IBM Corp., New 
York, USA). In the univariate analysis, variables with a p 
value of <0.25 were selected for entry in the final multi-
variate model. A p value of <0.05 was considered signifi-
cant. Categorical data were expressed in frequencies and 
percentages whereas continuous variables were presented 
as median and IQR. Depending on the distribution of 
continuous variables, non- parametric tests were used for 
calculation of p values, where applicable.
RESULTS
Out of 107 available patients’ medical records, a total of 
98 MDR patients were included in this retrospective chart 
review (see figure 1). Baseline characteristics of these 98 
patients are summarised in table 1. Patients were treated 
for a median period of 20 months (20–24; min, max). 
Pulmonary TB was the most common diagnosis in 93 
(94.8%) patients; 5 (5.1%) had extrapulmonary TB. The 
majority of the patients—87 (88.7%)—had prior anti- TB 
therapy. Among these retreated patients, 34 (39.1%) had 
failed on a 6- month treatment regimen with first- line 
drugs and 19 (21.8%) had failed on the 8- month retreat-
ment regimen with first- line drugs including strepto-
mycin (table 2).
The median time to sputum smear conversion (n=75) 
was 60 days (60–90 IQR) and culture conversion (n=81) 
was also 60 days (60–90 IQR); two patients remained 
culture positive after intensive treatment characterised 
by the growth of NTM (Nontuberculous mycobacteria) 
later on (8th and 10th month), respectively. Treat-
ment outcomes of the study population (n=98) were 
as follows: 73 (74.5%) patients were cured, 12 (12.2%) 
completed the treatment, 3 (3.1%) were lost to follow- up, 
4 (4.1%) were transferred out, 5 (5.1%) died and 1 (1%) 
failed MDR- TB treatment. Among five deaths, three 
Figure 1 Flow chart of the study population. MDR- TB, 
multidrug- resistant tuberculosis.
Table 1 Demographic and clinical characteristics of 
included patients (n=98)
Age, years 29 (22–40)
Body weight at admission, kg 48 (44–58)
Body weight after 8 months of treatment, kg 
(n=85)
56 (47–60)
Gender, male (n=98) 56 (57.1)
Comorbidity (n=80)
  HIV 6 (7.5)
  Diabetes mellitus 6 (7.5)
  Seizure disorder 4 (5.0)
  Cardiovascular disease 1 (1.3)
  Active hepatitis/cirrhosis 1 (1.3)
  Osteoporosis 1 (1.3)
  Gastric ulcer 1 (1.3)
Diagnosis (n=96)
  Sputum 92 (95.8)
  Others (pleural fluid, lymph node aspirate) 4 (4.2)
Radiographic findings (n=83)
  Cavitary lesions 7 (8.4)
  Bilateral pulmonary involvement with 
cavitary lesions
10 (12.1)
  Bilateral pulmonary involvement without 
cavitary lesions
31 (37.4)
  Non- cavitary non- bilateral pulmonary 
involvement
33 (39.8)
  Normal chest finding 2 (2.4)
Drug resistance, phenotypic testing
  Streptomycin (n=14) 13 (92.9)
  Isoniazid (n=24) 24 (100)
  Rifampicin (n=88) 88 (100)
  Ethambutol (n=74) 39 (52.7)
Drug resistance, genotypic testing
  Isoniazid (n=9), InhA wildtype and katG Mut 
1
9 (100)
  Rifampicin (n=9), rpoB (mutation-3) 9 (100)
Ethambutol (n=74), emB- Mut1 38 (51.4%)
Categorical data are expressed in frequencies and percentages 
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died during the first 2 months of TB treatment, one 
committed suicide at month 14 of treatment and one 
critically ill child died at an intensive care unit during 
the first month of TB treatment. In our study, 86.7% had 
successful outcome (n=98) based on standards proposed 
by Laserson et al.13 20 In a univariate analysis, only days to 
culture conversion was significantly (p=0.002) associated 
with treatment outcomes. Results of univariate analysis 
are available in online supplementary material.
The lab test results at three different time periods 
in patients with MDR- TB are summarised in table 3. 
The majority of patients had hyperuricaemia. Based on 
alanine amino transferase (ALT), aspartate transaminase 
and bilirubin levels, only one patient had to temporarily 
interrupt the treatment due to hepatotoxicity. The levels 
of ALT did not escalate more than 3–5 times the upper 
limit of normal in the majority of patients. Moreover, 
information on side effects of medical treatment was avail-
able for 97 patients. Seven (7.2%) out of 97 patients did 
not experience any side effects. Side effects observed in 
the remaining 90 (92.8%) patients are shown in table 4. 
Psychosis was the most common side effect leading to the 
withdrawal of cycloserine, which was then replaced by 
clofazimine. Hepatotoxicity led to the discontinuation of 
pyrazinamide in only one patient.
Furthermore, we evaluated the proportion of patients 
with available DST results on first- line and second- line 
drugs for their potential eligibility in a shorter 9- month 
MDR- TB regimen. The results from both phenotypic and 
genotypic testing revealed that 52% of the patients with 
MDR- TB (n=74) had resistance to ethambutol. Based on 
results of this study, if ethambutol resistance were to be 
considered, only 48% of patients with MDR- TB would 
be eligible for shorter 9- month regimen. However, in 
programmatic settings like Nepal resistance to etham-
butol is not taken into account because only fluoro-
quinolones and second- line injectables are considered 
important core drugs in a the shorter 9- month regimen. 
There is a documented evidence that the regimen fails 
only when the isolate is resistant to core drugs but not 
companion drugs (ethambutol, pyrazinamide or clofaz-
imine).12 Therefore, patients had to meet three criteria 
to be eligible for a shorter 9- month regimen in Nepal: 
confirmed susceptibility to injectables, confirmed 
susceptibility to fluoroquinolines and low- level isoni-
azid resistance: InhA mutations for isoniazid (patients 
with katG mutations were disqualified and started on a 
longer 18–20 month regimen). Among 38 patients with 
MDR- TB who had initial resistance to ethambutol, all of 
them achieved favourable treatment outcomes (Laserson 
recommendations). Of 38 patients, 32 (84.2%) were 
deemed cure and 6 (15.8%) completed the treat-
ment. However, ethambutol was not part of the longer 
18–20 month MDR- TB regimen.
In our study, 23 patients categorised as high- risk group 
to poor MDR- TB treatment would have been eligible 
for TDM (table 5). Among these 23 patients: 6 patients 
had HIV, 6 had diabetes mellitus, 1 had liver cirrhosis, 1 
had gastric ulcer and 1 elderly patient had extremely low 
creatinine clearance which is of relevance to levofloxacin 
pharmacokinetics; and 8 patients did not attain culture 
conversion in 90 days.
DISCUSSION
The study evaluated treatment results of current 
programmatic regimen before implementation of all- 
oral 18–20 month regimen which includes new drugs like 
bedaquiline and delamanid, at the TB referral clinic of 
Nepal.
We found a high treatment success rate of 86.7% for 
our MDR- TB cohort. In a previous study by Malla et al, 
70% of the outpatients with MDR- TB were reported to be 
cured on a regimen containing ofloxacin.22 The improved 
outcome may be explained by the use of the levofloxacin 
instead of ofloxacin and early prescreening of patients 
for resistance to second- line drugs.22 However, results 
from our study should be interpreted with caution. First, 
patients who were classified as pre- XDR were excluded 
because they were put on a different regimen containing 
moxifloxacin and not levofloxacin. However, moxiflox-
acin should not be used if documented resistance to FQs 
(Fluoroquinolones). Second, our study is a single- centre 
study. Only patients managed in the GENETUP referral 
clinic were studied. This centre in the capital of Nepal 
is well equipped with molecular and phenotypic DST. 
In this centre, the treatment success rates for MDR- TB 
cases were 69.0% in 2015, 86.6% in 2016 and 86.5% in 
2017. Owing to its high treatment success, the model of 
care implemented by the GENETUP clinic should also be 
adopted by other MDR- TB treatment sites in Nepal.
One of the striking observations from this study was 
that the majority of patients with MDR- TB had prior 
anti- TB therapy and 60% had failed a 6–8 month treat-
ment regimen with first- line drugs and streptomycin. 
This is in contrast with the high success rate of drug- 
susceptible TB and not on par with the incidence of 
MDR- TB (15.4% of retreatment cases are MDR- TB based 
on drug resistance survey carried out in 2011/2012).19 
Despite use of DOTS, these patients might have been 
patients with MDR- TB misdiagnosed as drug- susceptible 
TB due to unavailability of GeneXpert MTB/RIF and 
Table 2 Patients with prior tuberculosis (n=87)
Causes of failure Cases Percentage
Treatment after failure of category I 34 39.1
Treatment after failure of category II 19 21.8
Treatment after lost to follow- up 1 1.1
Relapse 33 37.9
Total 87 100
Category I included treatment with isoniazid, rifampicin, 
pyrazinamide and ethambutol whereas, category II included 
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therefore put on an ineffective first- line regimen; or they 
might have acquired resistance to rifampicin/isoniazid 
during the course of treatment with first- line drugs; or 
they may have been reinfected with drug- resistant bacilli 
from a source patient having MDR- TB. In Nepal, the 
primary drugs resistance is high; treating patients who 
failed on category I treatment with addition of strepto-
mycin might have resulted in higher failure of category 
II treatment. The routine drug resistance survey in Nepal 
showed a higher proportion of resistance to second- line 
drugs, with resistance to fluoroquinolones alone at 
39.3% among patients with MDR- TB.19 This implies that 
40% of the patients with MDR- TB in Nepal might require 
pre- XDR TB treatment. In 2017 alone, around 35.4% of 
confirmed MDR- TB cases were pre- XDR (91 pre- XDR 
cases among 257 diagnosed MDR- TB cases).19 In 2017, 
overall treatment success rate of pre- XDR TB was 58% 
and XDR TB was 61%. The death rate was quite high 
among XDR TB cases (39%) and encouragingly, there 
was no lost to follow- up among XDR TB cases. Since 
Table 3 Hepatic enzymes and renal function tests in patients with multidrug- resistant tuberculosis
Normal reference 









Hepatic enzymes       
































































Renal markers       
  Creatinine, µmol/L










   Females 
n<107
44.2–106.8


































  Uric acid, 
mmol/L
  M: n<0.42











Data are presented as median (IQR) for all continuous variables. Renal function was defined based on creatinine level. Creatinine 
level=132–194 µmol/L was considered impaired and >203 µmol/L was considered severely impaired; hyponatraemia=serum sodium below 
135 mmol/L, severe hyponatraemia was less than 115 mmol/L; hypokalaemia=potassium less than 3.5 mmol/L; hyperkalaemia=potassium 
levels higher than 6 mmol/L. Hyperuricaemia=levels above the upper limit of normal for both males and females.
*Paired t- test.
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clinical diagnosis of pre- XDR TB is not possible, this calls 
for a massive scale up of genotypic susceptibility testing 
in decentralised TB treatment centres and subcentres, 
to adequately diagnose patients and start appropriate 
treatment.23 Moreover, as per local guidelines, previously 
diagnosed patients with TB and a typical TB chest X- ray 
failing on 6- month treatment regimen with first- line 
drugs and on the 8- month retreatment regimen with first- 
line drugs including streptomycin are put on MDR- TB 
treatment. This is because overall treatment outcomes 
of patients who fail both 6 and 8 month regimens are 
unacceptably poor if not placed on MDR- TB regimen. 
This might improve significantly in future as GeneXpert 
is being rolled out massively in Nepal, with a total of 55 
GeneXpert centres at present.
The side effects of MDR- TB drugs in patients remain a 
major concern but most were managed without change 
of the MDR- TB regimen. Regarding eligibility of patients 
for the shorter 9- month MDR- TB regimen, it is unclear 
if patients with resistant strains to ethambutol would 
qualify. Van Deun et al argued that full susceptibility to 
ethambutol and isoniazid was not of paramount impor-
tance for patients to qualify for treatment with the shorter 
regimen.24 This could be problematic and result in inclu-
sion of patients with different drug resistance profiles 
compared with those at trial sites in Niger, Cameroon 
and Bangladesh on which the 9- month regimen is 
based.25 In a recently published study by Piubello et al, 
successful outcomes were not affected by initial resis-
tance to companion drugs (ethambutol, pyrazinamide 
and clofazimine).12 In line with their study, initial resis-
tance to ethambutol did not seem to negatively affect 
treatment outcomes in our study.
Since January 2018, the NTP of Nepal has endorsed 
the 9- month shorter regimen for the treatment of 
MDR- TB with weight band moxifloxacin dosing 
(600 mg or 800 mg) in all TB treatment centres, with 
the support of the Damien Foundation. At present, 
resistance to ethambutol and isoniazid (due to shortage 
of test kits) is not considered while determining eligi-
bility. Patients are eligible if deemed susceptible to fluo-
roquinolones and aminoglycosides. Between July 2018 
and July 2019, 72% (31/43) of the registered MDR- TB 
patients were eligible for a shorter 9- month treatment 
regimen in the GENETUP clinic. The remaining 28% 
received programmatic standardised MDR- TB regimen 
with injectable agents (kanamycin). Encouragingly, 
with the implementation of all- oral 18–20 month 
regimen, the trend is shifting with more patients being 
switched to all- oral regimen over shorter 9- month 
regimen containing injectable agents. The treatment 
outcome results from the shorter 9- month regimen in a 
high- incidence, high- fluoroquinolones- resistant setting 
like Nepal will be communicated to the TB community 
likely in 2020.
Table 4 Side effects associated with the multidrug- 
resistant tuberculosis treatment













Hearing loss Kanamycin 6 (6.7)












  Depression Cycloserine 5 (5.6)
  Psychosis Cycloserine 4 (4.4)
  Suicidal thoughts Cycloserine, 
levofloxacin
2 (2.2)
Table 5 Therapeutic drug monitoring (TDM) indications**
TDM indication (n=80) N (%) Effects on pharmacokinetics of anti- TB drugs
Diabetes mellitus 6 (7.5) Diabetes induced gastroparesis leading to either delayed absorption, 
malabsorption or altered clearance of anti- TB drugs
Concurrent HIV infection 6 (7.5) Reduced exposure of anti- TB drugs
Gastric ulcer 1 (1.3) Interference with absorption of anti- TB drugs
Liver cirrhosis 1 (1.3) Altered drug metabolism, prolonged effect of parent drug, reduced effect of 
prodrugs, increase in toxic metabolites
Impaired renal clearance 1 (1.25) Over exposure of renally cleared drugs, increased toxicity, require dose 
reduction
Slow treatment response 
(n=73)
8 (11) Possibly suboptimal exposure of anti- TB drugs due to interindividual 
variabilities
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In relation to drug exposure, 30% of the patients at 
the GENETUP clinic who were enrolled for a prospec-
tive pharmacokinetic study between 2016 and 2017 did 
not meet the established levofloxacin target for effi-
cacy on one time a day 750–1000 mg dosing.26 These 
Nepalese patients would have benefitted from dose 
adjustments based on TDM.26–29 In the official clin-
ical practice guidelines,21 TDM is recommended to 
all patients on second- line drugs, but in settings with 
high TB endemicity these recommendations have yet 
to see the daylight.30 MDR- TB treatment centres in 
countries such as the Netherlands, Sweden, Germany 
and USA routinely employ plasma/serum TDM to esti-
mate Cmax and AUC0-24 (Area under the concentration- 
time curve) of core drugs like moxifloxacin, linezolid 
and aminoglycosides, among others which has helped 
ensure adequate drug exposure and minimise associ-
ated toxicity. The treatment outcomes for MDR- TB in 
these centres are comparable to those reported glob-
ally for drug- susceptible TB (above 75%).30 Therefore, 
it is about time that TDM is incorporated as a part of 
programmatic care also in settings like Nepal.
This study has several limitations. First, being a retro-
spective study from a single centre, the generalisability 
is limited. However, due to the excellent programmatic 
care in this centre, it could serve as role model for other 
centres in the country and region. Second, lack of differ-
ence in treatment outcomes between predisposing risk 
factors and non- risk factors groups could be due to the 
low statistical power and high proportion of cure and 
completion rates compared with lost to follow- up, death 
and relapse, due to unavailability of patient informa-
tion in the latter group. Pooling individual patient data 
from several treatment outcome studies as has been 
done by the Canadian team led by Menzies would likely 
improve the statistical power for future studies to detect 
a difference in response.31 It is also imperative to have 
a standardised data collection strategy for wider gener-
alisation of results. Nevertheless, our study has a major 
strength. The availability of complete treatment outcome 
data along with all significant clinical variables and DST 
results (phenotypic and genotypic) makes it relevant and 
provides a data- rich description of patients with MDR- TB 
treated in an outpatient setting. The study will likely be 
used to compare with results from the 9- month and all- 
oral MDR- TB regimens.
In conclusion, the standardised MDR- TB regimen 
appears well tolerated in patients; none of the adverse 
events resulted in a change of regimen. Implementation 
of the new WHO oral MDR- TB treatment regimen may 
further improve treatment results. For patients resistant 
to fluoroquinolones or second- line injectables, all- oral 
regimen might be the best option and for those without 
resistance to fluoroquinolones or second- line injectables, 
the shorter regimen is indicated. The 9- month regimen 
and TDM should be considered as part of programmatic 
care.
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